1042722-99-5

Basic information

• Product Name: methyl 3-[(2S,3R)-1-(4-fluorophenyl)-2-(4-hydroxyphenyl)-4-oxoazetidin-3-yl]propionate
• Synonyms: methyl 3-[(2S,3R)-1-(4-fluorophenyl)-2-(4-hydroxyphenyl)-4-oxoazetidin-3-yl]propionate
• CAS NO: 1042722-99-5
• Molecular Weight: 343.355
• Mol File: 1042722-99-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: methyl 3-[(2S,3R)-1-(4-fluorophenyl)-2-(4-hydroxyphenyl)-4-oxoazetidin-3-yl]propionate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 3-[(2S,3R)-1-(4-fluorophenyl)-2-(4-hydroxyphenyl)-4-oxoazetidin-3-yl]propionate(1042722-99-5)
• EPA Substance Registry System: methyl 3-[(2S,3R)-1-(4-fluorophenyl)-2-(4-hydroxyphenyl)-4-oxoazetidin-3-yl]propionate(1042722-99-5)

Safety Data

• Hazardous Substances Data: 1042722-99-5(Hazardous Substances Data)

Upstream product

• 204589-80-0 methyl 3-((2S,3R)-2-(4-(benzyloxy)phenyl)-1-(4-fluorophenyl)-4-oxoazetidin-3-yl)propanoate 

Downstream Products

• 1042723-03-4 methyl 3-{(2S,3R)-2-[4-(4-bromobenzyloxy)phenyl]-1-(4-fluorophenyl)-4-oxoazetidin-3-yl}propionate 
• 1042723-07-8 methyl 3-{(2S,3R)-1-(4-fluorophenyl)-2-[4-(4-methoxybenzyloxy)phenyl]-4-oxoazetidin-3-yl}propionate 
• 1042723-16-9 methyl 3-{(2S,3R)-2-[4-(tert-butyldimethylsilyloxy)phenyl]-1-(4-fluorophenyl)-4-oxoazetidin-3-yl}propionate 
• 1042723-17-0 methyl 3-{(3R,4S)-1-(4-fluorophenyl)-2-oxo-4-[4-(tetrahydro-2H-pyran-2-yloxy)phenyl]azetidin-3-yl}propanoate 
• 1042723-00-1 methyl 3-{(3R,4S)-1-(4-fluorophenyl)-2-oxo-4-[4-(trityloxy)phenyl]azetidin-3-yl}propionate 
• 1042723-15-8 methyl 3-{(2S,3R)-2-[4-(biphenyl-4-ylmethoxy)phenyl]-1-(4-fluorophenyl)-4-oxoazetidin-3-yl}propionate 
• 1042723-05-6 methyl 3-{(2S,3R)-2-[4-(4-chlorobenzyloxy)phenyl]-1-(4-fluorophenyl)-4-oxoazetidin-3-yl}propionate 
• 1042723-14-7 methyl 3-{(2S,3R)-1-(4-fluorophenyl)-2-[4-(4-nitrobenzyloxy)phenyl]-4-oxoazetidin-3-yl}propionate 

Relevant articles and documents

Process for the preparation of ezetimibe and derivatives thereof

The present invention relates to the method of preparing of ezetimibe and in particular to novel intermediates for its synthesis and an improved process for preparing such intermediates. Said intermediates may be obtained in high yields and purity in a fast and cost efficient manner. The present invention relates to a novel crystalline form of ezetimibe as well.